CatalystWire
← Back to feed

Oxford Biodynamics

OBD · AIM · Health Care · mcap £16m today, £16m on 27 Aug

New CEO resets, then buys · Early 1/3
Pattern evidence · every line sourced
  1. New CEO or CFO, 27 Aug: The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad. RNS
  2. Watch: next signal would be “Guidance cut” – “below expectations” or a profit warning, within 180 days.

AI summary with checked claims arrives with the nightly run. These lines are the matched extracts.

All announcements

All RNS · 40 Key events · 18 Pattern signals · 1
  1. 01 Oct 26
    Extension of Timetable in relation to Placing

    Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”).

    RNS 9802755 ↗
  2. 18 Sep 26
    PDMR Dealing / Grant of Share Options
    RNS 9778541 ↗
  3. 17 Sep 26
    Holding(s) in Company
    RNS 9776277 ↗
  4. 03 Sep 26
    Orion reveals link between five fatigue conditions

    Study finds five major fatigue-related conditions converge on shared regulatory networks when analysed using Oxford BioDynamics' EpiSwitch® Orion platform

    RNS 9754462 ↗
  5. 01 Sep 26
    Holding(s) in Company
    RNS 9749182 ↗
  6. 01 Sep 26
    Holding(s) in Company
    RNS 9749181 ↗
  7. 28 Aug 26
    Holding(s) in Company
    RNS 9746425 ↗
  8. 28 Aug 26
    Holding(s) in Company
    RNS 9746420 ↗
  9. 27 Aug 26
    SIGNAL 1 New CEO or CFO

    The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad.

    Board Appointment · RNS 9742146 ↗
  10. 26 Aug 26
    Result of General Meeting
    RNS 9741364 ↗
  11. 13 Aug 26
    Partnership with Dubai London Clinics & Hospitals

    Oxford BioDynamics partners with Dubai London Clinics & Hospitals to bring EpiSwitch® PSE to the UAE

    RNS 9719108 ↗
  12. 10 Aug 26
    Fundraising, Posting of Circular & Notice of GM

    Oxford, UK - 10 August 2026 - Oxford Biodynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and...

    RNS 9713768 ↗
  13. 28 Jul 26
    First commercial agreement for EpiSwitch® Orion

    Oxford BioDynamics signs first commercial agreement for its EpiSwitch® Orion 3D genomics discovery platform

    RNS 9689971 ↗
  14. 17 Jul 26
    Holding(s) in Company
    RNS 9675237 ↗
  15. 17 Jul 26
    Holding(s) in Company
    RNS 9674717 ↗
  16. 30 Jun 26
    US contract sales partnership

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9643232 ↗
  17. 30 Jun 26
    Half-year Results

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9643173 ↗
  18. 30 Jun 26
    Appointment of Chief Executive Officer New CEO

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9643006 ↗
  19. 15 Apr 26
    Board Appointment

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9520343 ↗
  20. 30 Mar 26
    Holding(s) in Company
    RNS 9498806 ↗
  21. 20 Mar 26
    Holding(s) in Company
    RNS 9484892 ↗
  22. 03 Mar 26
    OBD to present at PMWC 2026

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9455772 ↗
  23. 17 Feb 26
    Change of Nominated Adviser

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9433547 ↗
  24. 27 Jan 26
    Holding(s) in Company
    RNS 9389556 ↗
  25. 26 Jan 26
    Result of AGM
    RNS 9387205 ↗
  26. 26 Jan 26
    Directorate Change

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9385679 ↗
  27. 22 Dec 25
    Publication of 2025 Annual Report

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9312848 ↗
  28. 16 Dec 25
    Preliminary Results and Notice of AGM

    ("OBD" or the "Company" and, together with its subsidiaries, the "Group")

    RNS 9298665 ↗
  29. 09 Dec 25
    Notice of Results
    RNS 9285406 ↗
  30. 03 Dec 25
    Statement re share price, update on EpiSwitch PSE
    RNS 9271801 ↗
  31. 25 Nov 25
    Holding(s) in Company
    RNS 9256362 ↗
  32. 12 Nov 25
    Holding(s) in Company
    RNS 9227762 ↗
  33. 11 Nov 25
    Holding(s) in Company
    RNS 9226848 ↗
  34. 11 Nov 25
    Holding(s) in Company
    RNS 9226847 ↗
  35. 11 Nov 25
    Holding(s) in Company
    RNS 9226845 ↗
  36. 10 Nov 25
    PDMR Dealing / Grant of Share Options
    RNS 9222247 ↗
  37. 07 Nov 25
    Result of General Meeting/PDMR Dealings
    RNS 9220041 ↗
  38. 22 Oct 25
    Fundraising, Posting of Circular & Notice of GM

    The Placing and the Subscriptions (together the "Fundraising") are being carried out at an issue price of £0.003 per Ordinary Share of £0.001 each (the "Issue Price").

    RNS 9185852 ↗
  39. 14 Oct 25
    OBD in New Report on NHS Prostate Cancer Screening

    Prostate Cancer Research NHS screening report highlights OBD's EpiSwitch PSE

    RNS 9168773 ↗
  40. 08 Oct 25
    OBD and UEA develop test for Chronic Fatigue

    OBD and UEA develop breakthrough diagnostic test for Chronic Fatigue Syndrome

    RNS 9156866 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.